McKinsey’s Harriet Keane, Rachel Moss, Aliza Apple and Valentina Sartori take a look at how drug companies are turning to the concept of agility to transform their R&D functions. The authors note the particular challenges of R&D transformations in the pharma sector, including high investment levels, long development timelines, and high rates of failure beyond a company’s control; the initially “disorienting” move of typically risk-averse staff who prize rigidity and sequence over an agile model; intense competition with peers as innovation cycles accelerate; and the need to serve diverse external stakeholders, including regulators, payers, providers and patients, that can add complexity to transformation planning.
About The Author
Providing insight into technology and innovation in the legal, accountancy property and consultancy sectors. Alternative Insights brings together news, commentary and thought leadership about digital transformation across the entire professional services industry. We collate industry stories on innovation, technology and transformation in the legal, accountancy, management and property consultancy sectors, giving you access to the latest thinking about tech and innovation in the professions.
August 5, 2019
June 22, 2020
November 26, 2019